While OpenAI is putting off its plans for an IPO into next year, Anthropic seems determined to rush full speed ahead. Given ...

ADARx is the only maker of RNA-based drugs to go public since 2024 and the first RNAi biotech to price an IPO in the U.S. in ...

Nscale filed for a NYSE IPO with $140.6M in H1 revenue, 1,252% growth, a $103B backlog, and $1B in losses, spotlighting ...

Anthropic's IPO path is fueling a powerful AI safety donor network ahead of the 2026 midterms, with $20M in advocacy spending ...

Anthropic's IPO prospects are energizing donors to push for stronger AI safeguards, reshaping Washington's political fundraising ahead of the elections.

Unix AI targets IPO amid surging Chinese demand for humanoid robots and expands globally, with growth in Singapore and India driving international sales.

Palantir Technologies CEO Alex Karp has raised fresh questions about whether companies developing advanced artificial ...

We recently asked whether the trillion-dollar AI capex gap could become Nvidia’s trap and Microsoft’s opportunity, and ...

AI drug discovery is about to get a public-market test with unusually recognizable backers. Iambic Therapeutics filed for a U ...

The technology market has entered a period where a handful of companies can command valuations that once required an entire ...

Nscale is entering the public markets with extraordinary growth, massive customer commitments, and some numbers investors ...